VAXCYTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.72 USD | +1.10% |
|
-0.18% | -3.31% |
| 25/04 | Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing | MT |
| 22/04 | Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.6B 551B |
|---|---|---|---|---|---|
| Net income 2024 * | -464M -38.69B | Net income 2025 * | -509M -42.44B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-14.3
x | P/E ratio 2025 * |
-13.5
x | Employees | 254 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vaxcyte, Inc.
More recommendations
More press releases
More news
| 1 day | +1.10% | ||
| 1 week | -0.18% | ||
| Current month | -11.11% | ||
| 1 month | -9.94% | ||
| 3 months | -5.58% | ||
| 6 months | +25.79% | ||
| Current year | -3.31% |
1 week
58.10
63.22
1 month
58.1069.69
Current year
53.8382.04
1 year
41.6082.04
3 years
15.5182.04
5 years
15.5182.04
10 years
15.5182.04
| Managers | Title | Age | Since |
|---|---|---|---|
Jeff Fairman
FOU | Founder | 60 | 27/13/27 |
Grant Pickering
FOU | Founder | 56 | 27/13/27 |
| Director of Finance/CFO | 55 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Grant Pickering
FOU | Founder | 56 | 27/13/27 |
| Director/Board Member | 58 | 16/21/16 | |
Michael Kamarck
BRD | Director/Board Member | 73 | 27/21/27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.27% | 0 M€ | 0.00% | - | |
| 0.10% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 60.72 | +1.10% | 594,302 |
| 25/24/25 | 60.06 | -0.40% | 1,566,189 |
| 24/24/24 | 60.3 | -0.95% | 701,758 |
| 23/24/23 | 60.88 | -1.17% | 665,981 |
| 22/24/22 | 61.6 | +1.27% | 627,167 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Calendar
06/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
60.72
USD
Average target price
103.3
USD
Spread / Average Target
+70.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.31% | 6.6B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- PCVX Stock
